References
- Egilman DS, Rankin Bohme S. Over a barrel: corporate cor-ruption of science and its effects on workers and the environ-ment. Int J Occup Environ Health. 2005; 11: 331–7. http:www.ijoeh.com.
- LaDou J. Occupational medicine in the United States: a proposal to abolish workers' compensation and reestablish the public health model. Int J Occup Environ Health. 2006; 12: 154–68.
- Sass JB, Castleman B, Wallinga D. Vinyl chloride: a case study of data suppression and misrepresentation. Environ Health Per-spect. 2005; 113: 809–12.
- Richter E, Soskolne CL, LaDou J: Efforts to stop repression bias by protecting whistleblowers. Int J Occup Environ Health. 2001; 7: 68–71.
- Kuehn RR. Suppression of environmental science. Am J Law & Med. 2004; 30: 333–69.
- Mutetwa B, Chikonyora M, Dozva R, Mazibuko D. Chrysotile fibre levels in asbestos-cement manufacturing in Zimbabwe. African Newsletter on Occupational Health and Safety. 2005; 15: 66–68. http://www.ttl.fl/africannewsletter or http://www.ttl.fi/nr/rdonlyres/39784837-0345-4122-974d-822b6cec29ca/0/africannewsletter305.pdf.
- Bailar JC 3rd, Ballal SG, Boback M, et al. FIOH-sponsored Newsletter misrepresents asbestos hazards in Zimbabwe. Int J Occup Environ Health. 2006; 12: 254–8.
- Wiist WH. Public health and the anticorporate movement: rationale and recommendations. Am J Public Health. 2006; 96: 1370–5.
- Samuels SW. Time to consider real environmental criminal laws? July 31, 2006. Internet message to LaDou J.
- Teitelbaum D. Internet message to Sheldon Samuels, July 31, 2006.
- LaDou J. The rise and fall of occupational medicine in the United States. Ana J Prey Med. 2002; 22: 285–95.
- LaDou J. Occupational medicine: the case for reform. Arn J Prey Med. 2005; 28: 396–402.
- Sass J. Lockheed Martin and the White House working Together to weaken regulation of chemicals leaching from military super-fund sites, Int J Occup Environ Health. 2004; 10: 330–4.
- Breilh J, Branco JC, Castleman BI., et al Texaco and its consult-ants [letter], IntJ Occup Environ Health, 2005; 11: 217–20.
- Egilman DS, Billings MA. Abuse of epidemiology: automobile manufacturers manufacture a defense to asbestos liability. Itati Occup Environ Health. 2005; 11: 360–71.
- Egilman DS, Scout. Corporate corruption of science: the case ofchromium (VI). Int J Occup Environ Health. 2006; 12: 169–76.
- Scout, Egilman D. The case of chromium (VI). Int J Occur) Env-iron Health. 2006; 12: 426–8.
- Bailar JC 3rd, Cicolella A, Harrison RJ, et al. IBM, Elsevier Sci-ence, and academic freedom. Arn J Ind Med. 2007; in press.
- Melnick R.L. Suppression of crucial information in the IARC evaluation of DEHP. Rig Occup Environ Health, 2003; 9: 84–5; discussion 89.
- Infante PF, Schuman LD, Dement J, Huff J. Fibrous glass and cancer, Arn J Ind Med, 1994: 26:559–84.
- Infante PF, Schuman LD, Huff J. Fibrous glass insulation andcancer: response and rebuttal. Am J Ind Med. 1996; 30: 113–20.
- Axelson O, Balbus JM, Cohen G, et al, Re: Regulatory toxicol-ogy and pharmacology. Int J Occup Environ Health, 2003; 9: 386-9; author reply 389-90.
- Jacobson MF, Sharpe VA, Angell M, et al. Editorial policies on financial disclosure. Nat Neurosci. 2003; 6: 1001.
- Ashford NA, Castleman B, Frank AL., et al The International Commission on Occupational Health (ICOH) and its influence on international organizations. Int J Occup Environ Health. 2002; 8: 156–62.
- Richter ED, Berman T. Seattle and the ICOH: the view from the other side of the globe reditoriall. Int J Occup Environ Health. 2000; 6: 161–3
- Wattersort A. ICOH and the pesticide industry [editorial]. Int J Occup Environ Health. 2000; 6: 73–6.
- LaDou J. The asbestos cancer epidemic. Environ Health Per-spect. 2004: 112:285–90
- Castleman B, Lernen R. The manipulation of international sci-entific organizations. Int J Occup Environ Health. 1998; 4: 53–5.
- Castleman B. Global corporate policies arid international “double standards” in occupational and environmental health. Int J Occup Environ Health. 1999; 6: 61–4.
- Watterson A. Pesticide health and safety and the work and impact of international agencies: partial successes and major failures. Int J Occup Environ Health. 2001; 7: 339–47 [the case study is largely drawn from this reference].
- Sass JB, Colangelo A. European Union bans atrazine, while the United States negotiates continued use. Int J Occup Environ Health. 2006; 12: 260–7.
- NIEHS and ACC establish grant program. Environ Health Per-spect. 2001; 109: 12.
- GAO.NIH and EPA need to improve conflict of interest reviews for research arrangements with private sector entities. U.S. Gov-ernmental Accountability Office. GA0-05-191, February 2005.
- 'roma& L. The IARC monographs program: changing attitudes towards public health, Int J Occup Environ Health, 2002;8:144 52.
- Huff J. IARC monographs, industry influence, and upgrading, downgrading, and under-grading chemicals: a personal point of view. International Agency for Research on Cancer. Int J Occup Environ Health. 2002; 8: 249–70.
- Melnick RL, Brody C, DiGiangi J, Huff J. The IARC evaluation of DEHP excludes key papers demonstrating carcinogenic effects. Int J Occup Environ Health. 2003; 9: 400–2.
- Klaunig JE, Babich MA, Baetcke KP., et al PPARalpha agonist-induced rodent tumors: modes of action and human relevance, Crit Rev Toxica 2003; 33: 655–780.
- Melnick EL, Karnel F, Huff J. Declaring chemicals “not carcino-genic to humans” requires validation, not speculation. Environ Health Perspect. 2003; 111: A203–4.
- Mirer FE. Comment from the union participant in the IARC Working Group that downgraded DEHP. Int J Occup Environ Health. 2003; 9: 85–7.
- Needleman H, Huffj. The International Agency for Research ort Cancer and obligate transparency. Lancet Oncol. 2005; 6: 920–1.
- Abrams H, Anderson H, Anderson J., et al Business interests influence IPCS/WHO. Arch Environ Health, 1996; 51: 338–40.
- Soffritti M, Belpoggi F, Degli Esposti D, Lambertini L, Mal& E, Rigano A. First experimental demonstration of the rnultipoten-tial carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ Health Perspect. 2006; 114: 379–85.
- NTP. Toxicology Studies of Aspartame (CAS No. 22839-47-0) in Genetically Modified (FVB Tg.AC Hemizygous) and B6.129-Cdkn2atmlRulp (N2) Deficient Mice and Carcinogenicity Studies of Aspartame in Genetically Modified [B6.129-Trp53tmlBrd (N5) Haplo-insufficient] Mice (Feed Studies). GMM-1. National Toxicology Program, Research Triangle Park, NC, October 2005; 1-222.
- Gordon G. FDA resisted proposals to test aspartame for years. Star Tribune, November 22, 1996. http://www.rnindfully.org/food/aspartanie-fda-resisted22nov96.1nrn.
- UCS. Restoring Scientific Integrity in Policymaking. An Investi-gation into the Bush Administration's Misuse of Science. Union of Concerned Scientists. 46 pages, 18 Feb 2004. http://www.ucsutsa.org/.